Although targeted therapy [13, 34] and pemetrexed-based chemotherapy [35, 36] appear to be particularly effective in ALK- and/or RET-positive patients when pathologic characteristics are not considered, it remains to be determined whether these therapeutic regimes also effectively improve OS in ALK- or RET-positive PPA patients. This evidence concerns the gene RET and primary progressive aphasia.